Understanding how two signaling pathways interact in bladder cancer
Official title: Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer
Funded at Dana-Farber Cancer Inst · NIH-11067846 · Data updated 2026-11-12
This study is looking at how two important pathways in bladder cancer work together and hopes to find new treatments that could help improve outcomes for patients battling this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $487,506 |
| NIH project number | 5R01CA289304-02 |
| Project ID | NIH-11067846 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with bladder cancer, particularly those with specific genetic alterations in the MAPK and PPARG pathways.
✕Less likely to help
Patients with non-bladder cancers or those whose tumors do not exhibit alterations in the MAPK or PPARG pathways may not benefit from this research.
What this research studies
This research investigates the interaction between the MAPK and PPARG signaling pathways in bladder cancer, which is a significant health concern with high rates of diagnosis and mortality. By analyzing genetic alterations in bladder tumors, the study aims to uncover how these pathways contribute to tumor behavior and patient outcomes. The researchers will explore the potential of new therapeutic agents that target these pathways to improve treatment options for patients with bladder cancer. This approach is informed by recent genomic data and aims to provide insights into more effective therapies.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that significantly improve survival rates and quality of life for bladder cancer patients.
How similar studies have gone: Other research has shown promising results in targeting similar pathways in various cancers, indicating that this approach may yield beneficial outcomes.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Mouw, Kent W — Dana-Farber Cancer Inst
- Study coordinator: Mouw, Kent W
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.